Document is current
Any future updates will be listed below
-
Authors
Burchert, Andreas https://orcid.org/0000-0002-8411-8844
Nicolini, Franck E.
le Coutre, Philipp
Saussele, Susanne https://orcid.org/0000-0003-0357-5785
Hochhaus, Andreas https://orcid.org/0000-0003-0626-0834
Tuere, Evin
Metzelder, Stephan K.
Pauck, Kim
Garn, Holger
Raifer, Hartmann
Huber, Magdalena https://orcid.org/0000-0002-2963-0693
Gattermann, Norbert
Crysandt, Martina
Schafhausen, Philippe
Bormann, Matthias
Radsak, Markus P. https://orcid.org/0000-0002-3991-5721
Guerci-Bresler, Agnès
Illmer, Thomas
Goebeler, Maria E.
Herhaus, Peter
Teichmann, Lino L.
Franke, Georg-Nikolaus https://orcid.org/0000-0001-8239-002X
Lang, Fabian
Krause, Stefan W. https://orcid.org/0000-0002-5259-4651
Möhle, Robert
Klausmann, Martine
Stegelmann, Frank https://orcid.org/0000-0003-2157-476X
Lutz, Christoph
Etienne, Gabriel
Stoltefuß, Andrea
Göthert, Joachim R.
Ernst, Thomas https://orcid.org/0000-0003-2147-489X
Abu-Samra, Maisun
Höffkes, Heinz-Gert
Neubauer, Andreas https://orcid.org/0000-0002-7606-8760
Wang, Ying
Weiland, Paul https://orcid.org/0000-0003-3175-8271
Otto, Clara
Kiessler, Lea
Weber, Theresa
Kroning, Lea
Nist, Andrea
Stiewe, Thorsten https://orcid.org/0000-0003-0134-7826
Hehlmann, Rüdiger
Aminossadati, Behnaz
Wittenberg, Michael https://orcid.org/0000-0003-4526-1856
Winterstein, Kerstin
Oellerich, Thomas https://orcid.org/0000-0001-6570-6125
Lechner, Marcus
Pfirrmann, Markus
Schade-Brittinger, Carmen
Klemm, Paul https://orcid.org/0000-0002-3609-5713
Michel, Christian
-
Funding
Funding for this research was provided by:
Deutsche Krebshilfe (70112020 und 70112841)
Deutsche Forschungsgemeinschaft (GRK2573)
Clinician Scientist program by the Philipps University Marburg
- License Information
-
More Information
Article History
Received: 28 October 2025
Revised: 26 November 2025
Accepted: 12 December 2025
First Online: 12 January 2026
Competing interests
: AB: research support: Novartis, AOP Health; honoraria: Novartis, Incite, AOP Health; FN: consultancy : Incyte Biosciences, Novartis, Kumquat biosciences; advisory boards: Novartis, Terns Pharmaceuticals, BMS/Celgene; honoraria: Novartis, GSK, Incyte Biosciences; PlC: honoraria: Novartis, Incyte, Enliven; SS: honoraria: Novartis, Incyte, Zentiva, Roche; research support: Novartis, BMS, Incyte; AH: research support: Novartis, BMS, Pfizer, Incyte, TERNS, Eliven; honoraria: Novartis; GE: consultancy: Incyte Biosciences, Novartis; advisory boards: Novartis, BMS; honoraria: Novartis, Incyte Biosciences; JG: honoraria: Incyte, Bristol-Myers Squibb, Pfizer, Novartis, AOP Orphan Pharmaceuticals; consultancy: Incyte, Bristol-Myers Squibb, Pfizer, Novartis, AOP Orphan Pharmaceuticals; SWK: honoraria: Eickeler; Travel support: Jazz, Alexion, Abbvie; MC: advisory Board: Novartis, Incyte; travel support: Novartis, Incyte; PS: consultancy/membership on a board or advisory committee: Novartis, AOP Orphan, Incyte, Pfizer; honoraria: Novartis, Pfizer; congress and travel support: Novartis, AOP Orphan; stock in publicly-traded company: Novartis; MR: Travel support: SOBI, AOP, AbbVie, Johnson & Johnson, BeOne. consultancy fees, honoraria: Pfizer, Novartis, MSD, GSK, BeOne, BMS, AOP; GNF: honoraria: Novartis, Zentiva, advisory board: Novartis, Zentiva; CM: honoraria: Incyte, Novartis. All other authors declare no competing financial interests.
